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inner histopathologic changes and 
disproportionate zone volumes 
in foetal growth plates following 
gestational hypoglycaemia in rats
Vivi f. H. Jensen1,2,3*, Anne-Marie Mølck1, Ingrid B. Bøgh1, Jette Nowak1, Birgitte M. Viuff1, 
Charlotte L. M. Rasmussen2, Louise pedersen2, Johannes J. fels4, Suzi H. Madsen4, 
fiona e. McGuigan3, Pernille Tveden-nyborg2, Jens Lykkesfeldt2 & Kristina e. Akesson3
Maternal hypoglycaemia throughout gestation until gestation day (GD)20 delays foetal growth 
and skeletal development. While partially prevented by return to normoglycaemia after completed 
organogenesis (GD17), underlying mechanisms are not fully understood. Here, we investigated 
the pathogenesis of these changes and significance of maternal hypoglycaemia extending beyond 
organogenesis in non-diabetic rats. Pregnant rats received insulin-infusion until GD20 or GD17, with 
sacrifice on GD20. Hypoglycaemia throughout gestation increased maternal corticosterone levels, 
which correlated with foetal levels. Growth plates displayed central histopathologic changes comprising 
disrupted cellular organisation, hypertrophic chondrocytes, and decreased cellular density; expression 
of pro-angiogenic factors, HIF-1α and VEGF-A increased in surrounding areas. Disproportionately 
decreased growth plate zone volumes and lower expression of the structural protein MATN-3 were 
seen, while bone ossification parameters were normal. Ending maternal/foetal hypoglycaemia on 
GD17 reduced incidence and severity of histopathologic changes and with normal growth plate volume. 
Compromised foetal skeletal development following maternal hypoglycaemia throughout gestation is 
hypothesised to result from corticosterone-induced hypoxia in growth plates, where hypoxia disrupts 
chondrocyte maturation and growth plate structure and volume, decreasing long bone growth. 
Maternal/foetal hypoglycaemia lasting only until GD17 attenuated these changes, suggesting a pivotal 
role of glucose in growth plate development.
It has previously been established that maternal hypoglycaemia may cause foetal growth restriction and in 
rodents, even short-term, maternal hypoglycaemia may disturb foetal skeletal development, reflected in 
decreased ossification and bone malformations1–4. The underlying mechanisms are, however, not clear; especially 
an understanding of the critical time windows of maternal hypoglycaemia and its duration to allow for normal 
versus abnormal foetal development is still lacking. We therefore established a model in non-diabetic rats to study 
the effect of sustained insulin-induced hypoglycaemia on foetal skeletal development5. Previously we showed that 
continuous maternal hypoglycaemia throughout gestation resulted in skeletal malformations, as well as decreased 
skeletal growth and bone mineral density5. In comparison hypoglycaemia lasting only until GD17, when organo-
genesis is completed, followed by normoglycemia allowed for near-normal development, emphasising that suffi-
cient glucose supply late in gestation is crucial6.
To elucidate the principal mechanisms underlying the observed foetal skeletal defects, we have taken a wider 
approach to assess histological changes and to identify potentially regulatory pathways for bone growth and cal-
cification. We hypothesised that hypoglycaemia disrupts regulation of the skeletal micro-environment by altering 
growth plate structure, as well as gene expression, and hormones essential for normal development of growth 
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plates and bone cells, and that these changes would be more severe when hypoglycaemia extended throughout 
gestation compared with only until end of organogenesis.
The investigational strategy builds on our animal model of maternal hypoglycaemia induced by continu-
ous infusion with human insulin (HI) lasting either throughout gestation until termination on GD20 or until 
GD17 (covering the embryonic period and organogenesis), followed by three days without insulin-infusion 
(GD17–20)6.
We used four main approaches: A descriptive histologic evaluation, quantitative histology, gene expression 
analysis, and finally, quantification of plasma hormones. The descriptive histologic evaluation consisted of record-
ing any histopathologic disruption of growth plate organisation, including immunohistochemistry to visualise 
distribution of collagens, as well as in situ hybridisation to evaluate local expression of anti-hypoxic factors in 
growth plates. The quantitative assessment included stereologic measurement of growth plate volumes, spongious 
zone volume, and relative osteoblast: osteoclast volume in ossification centres. Gene expression analysis included 
quantification of genes related to growth plate structural composition, bone oxygen balance, the IGF-1 pathway, 
and osteoblast/osteoclast differentiation and activity. Major hormones known to influence bone metabolism such 
as corticosterone, IGF-1, and thyroid hormones were measured.
The data from this study will enable a better understanding of the pathogenesis of foetal skeletal changes 
resulting from continuous hypoglycaemia throughout gestation to GD20 (HI-EoGest) versus hypoglycaemia last-
ing only until end of organogenesis on GD17 (HI-EoOrg) in non-diabetic animals.
Results
Descriptive histology. Histopathologic evaluation. Morphological changes localised the central longitu-
dinal area of the growth plate were observed in the foetal tibial growth plates of the HI-infused groups (Fig. 1). 
All foetuses receiving HI-infusion throughout gestation (HI-EoGest), showed changes, which were severe and 
extended across all growth plate zones (Fig. 1d). The changes were characterised by fewer chondrocytes, which 
had lost their columnar organisation and displayed pyknotic nuclei and/or hypertrophy. Additionally, borders 
between the four growth plate zones (resting, proliferative, hypertrophic, degenerative) were irregular and less 
well-defined; particularly between the hypertrophic and degenerative zones and at the boundary between the 
degenerative growth plate zone and spongious zone of the primary ossification centre.
Figure 1. Representative examples of histopathologic changes in foetal tibial growth plates resulting from HI-
infusion throughout gestation. (A) Grade 0, no changes. (B) Grade 1, minimal morphological changes centrally, 
involving all zones except reserve zone. (C) Grade 2, moderate morphological changes centrally, involving 
all zones except reserve zone. (D) Grade 3, severe morphological changes centrally (arrowheads), involving 
all zones, with loss of columnar organisation of chondrocytes, the few remaining chondrocytes appearing 
hypertrophic with pyknotic nuclei (insert). Degen, degenerative; Hyp, hypertrophic. Magnification: x100; insert 
x200.
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In contrast, when infused only until end of organogenesis (HI-EoOrg) approximately half the foetuses dis-
played histopathologic changes, and these were of moderate grade (Fig. 1c). Compared to CTRLs, the changes in 
the HI-EoOrg group were more pronounced.
Immunohistochemistry. In controls, extracellular collagen II staining was observed throughout the growth plates 
(Fig. 2a); similarly, in the HI-EoGest group, staining was present in the central hypocellular area (Fig. 2b). In 
controls, collagen X distribution in growth plates clearly defined the boundary between proliferative and hyper-
trophic zones through positive staining of peri-cellular regions of hypertrophic chondrocytes (Fig. 2c). While the 
HI-EoGest showed a similar pattern, the cell types were not easily recognized, and the positive zone was markedly 
disordered (Fig. 2d).
In situ hybridization. HI-EoGest foetal growth plates had pronounced positive staining for the pro-angiogenic 
factors HIF-1α and VEGF-A, locally restricted to the margin of the histopathologic changes (Fig. 3b,d). No pos-
itive staining was observed in controls (Fig. 3a,c), except for a few scattered positive cells in the degenerative 
zone and peri-articular cartilage in some of the control animals, which were not easily recognisable even at 100x 
magnification. Additionally, the peri-articular cartilage of foetal tibial and meta-tarsal joints displayed a markedly 
local increased HIF-1α expression (Fig. 3e–h). VEGF-A showed a similar expression pattern (data not shown).
As some basal expression of HIF-1α and VEGF-A is expected in growth plates, the lack of positive staining is 
likely due to the sensitivity being too low to detect this; however, since the staining was very marked in the cells 
surrounding the changes, showing a pronounced increase versus controls, this is not considered to significantly 
affect the results.
Quantitative histology. Stereologic volume quantification. Growth plates. HI-infusion throughout ges-
tation (HI-EoGest) resulted in decreased total growth plate volume (p = 0.0001, Fig. 4a) and reduced reserve, 
proliferative, and degenerative zone volumes (p < 0.0001–0.003, Fig. 4b–e). Disproportionately decreased total 
growth plate and zone volumes were reflected by increased relative volumes of the proliferative and hypertrophic 
zones (p = 0.0192; p = 0.0239), but conversely decreased the relative volume of the degenerative zone (p = 0.0436, 
Figure 2. Immunohistochemical staining for collagen II (A,B) and collagen X (C,D) in foetal tibial growth 
plates. Sections stained for collagen II and X (dark brown). (A) CTRL: No histopathologic changes, normal 
distribution of collagen II throughout the growth plate, (B) HI-EoGest: Grade 3 changes, normal distribution of 
collagen II including the central area. (C) CTRL: No histopathologic changes. Peri-cellular collagen X staining 
between hypertrophic zone chondrocytes, clearly defining the boundary between proliferative and hypertrophic 
zones (arrowhead), (D) HI-EoGest: Grade 3 changes. Peri-cellular collagen X staining distally in the growth 
plate, no clear distinction of cell types and no central staining, resulting in a “V”-shaped staining pattern 
(arrowheads) pushing into hypertrophic, degenerative, and spongious zones. (Magnification: x100).
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Figure 3. In situ hybridization for VEGF-A and HIF-1α in foetal tibial growth plates (A–D) and meta-tarsal 
joints (E-H). Sections stained for VEGF-A and HIF-1α (pink). Proximal tibial growth plate: (A) CTRL: No 
histopathologic changes or staining, (B) HI-EoGest: Grade 3 changes and positive intracellular VEGF-A 
staining (arrowheads) in the cells at the periphery of the changes, (C) CTRL: No histopathologic changes 
or staining, (D) HI-EoGest: Grade 3 changes and positive intracellular HIF-1α staining (arrowheads) in the 
periphery of the changes. Meta-tarsal joint: (E) CTRL: No positive staining for HIF-1α, (F) HI-EoGest: Positive 
intracellular HIF-1α staining in articular cartilage (arrowheads), (G) CTRL: No positive staining for HIF-1α, 
(H) HI-EoGest - Positive intracellular HIF-1α staining (arrowheads) in articular cartilage. (A–D, G + H, x100 
magnification; E + F, x40 magnification).
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Fig. 5). Recovering normoglycaemia after organogenesis (HI-EoOrg) resulted in increased total growth plate 
volume compared to the HI-EoGest (p = 0.0140), reaching control levels; similarly, the reserve, proliferative, 
and degenerative zone volumes did not differ from controls (p = 0.0007–0.0490). Relative zone volumes were 
in-between group HI-EoGest and CTRL levels.
Spongious zone. The absolute spongious zone volume was decreased in HI-EoGest animals (p = 0.0042), 
whereas volumes for the HI-EoOrg group ranged between HI-EoGest and CTRL groups (Fig. 4f). The ratio of 
spongious zone: total growth plate volumes was not affected by HI-infusion (mean ratios 0.10–0.11 ± 0.01–0.02 
for all three groups; mean CE ≤ 0.05 and SD ≤ 0.01 for all).
Osteoblasts and osteoclasts. Immunohistochemical staining of osteoblasts nuclei/osteoclasts cytoplasm is 
illustrated in Supplementary Fig. S1. The ratio of osteoblast: osteoclast volumes in primary ossification centres 
was not affected by HI-infusion, regardless of duration (mean ratios CTRL 1.74 ± 0.32; n = 13, EoGest 1.71 ± 0.41, 
n = 7, HI-EoOrg 1.73 ± 0.34, n = 11; mean CE ≤ 0.02 ± 0.1 for all groups).
Gene expression analysis. RT-qPCR quantification of foetal bone tissue mRNA levels. HI-infusion did not 
alter mRNA levels of cartilage collagens, hypoxia-related genes, the structurally related gene comp, genes related 
to the IGF-1 pathway nor osteoblast/osteoclast differentiation and activity (data not shown). In contrast, mRNA 
level of Matn-3, an additional structurally related gene, was decreased in HI-EoGest animals (p = 0.0222, data no 
shown), whereas recovering from hypoglycaemia after organogenesis (HI-EoOrg) resulted in normal mRNA level 
of this gene.
Figure 4. Absolute total growth plate and zone volumes in foetal long bones. Means ± SD and individual 
values. Absolute volumes of (a) Total growth plate, (b) (Res)erve zone, (c) (Prolif)erative zone, (d) (Hyper)
trophic zone, (e) (Deg)enerative zone and (f) (Spong)ious zone. Inserts (d,f): Enlarged scale. **p < 0.01, 
***p < 0.001 versus CTRL, #p < 0.05, ##p < 0.01, ###p < 0.001 HI-EoOrg versus HI-EoGest. One-way ANOVA 
with post hoc Tukey’s multiple comparisons test.
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plasma hormone levels. Maternal and foetal corticosterone. Maternal corticosterone levels were increased 
in HI-infused animals on GD17 (HI-GD17; p < 0.0082) and GD18 (HI-EoGest, p = 0.0241; HI-EoOrg p = 0.0172. 
Figure 6a,b), with no difference between these groups. On GD20, HI-EoGest corticosterone levels remained ele-
vated, whereas HI-EoOrg levels had returned to normal (p < 0.0001, Fig. 6c).
Figure 5. Relative volumes of tibial growth plate zones shown as percentage of total growth plate volume. 
Absolute zone volumes related to total growth plate volumes (group means). Each column represents 100% of 
the growth plates volumes. CTRL, n = 12; HI-EoGest, n = 8; HI-EoOrg, n = 11. *p < 0.05 versus CTRLs. One-
way ANOVA with post hoc Tukey’s multiple comparisons test.
Figure 6. Plasma corticosterone levels: maternal (a–c) and foetal (d). Means ± SD and individual values. (a) 
Maternal levels at sacrifice on GD17. (b) Maternal levels on GD18. (c) Maternal levels at sacrifice on GD20. (d) 
Foetal litter levels on GD20. Dotted line: LLOQ (lower limit of quantification: 50 nmol/l). Four samples assayed 
<LLOQ and were set to 50 nmol/L (dams: 1 CTRL, GD18; 1 HI-EoGest and 1 HI-EoOrg, GD20. Litter: 1 HI-
EoGest, GD20). *p < 0.05, **p < 0.01, ***p < 0.001 versus CTRLs. ###p < 0.001 HI-EoOrg versus HI-EoGest. (a) 
Unpaired two-tailed t-test, (b–d) One-way ANOVA with post hoc Tukey’s test.
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Litter corticosterone levels on GD20 differed between the three groups overall (p = 0.0478) but were not sig-
nificantly different between individual groups (Fig. 6d). Exclusion of one HI-EoGest outlier (<LLOQ) strength-
ened the association (p = 0.0030) such that HI-EoGest levels were higher on GD20 compared to CTRLs and 
HI-EoOrg (p < 0.01).
As maternal and litter corticosterone levels in the HI-EoGest group were elevated on GD20, we tested the 
correlation between levels in individual dams and corresponding litter and this was strong (Pearson r = 0.834, 
p = 0.010, Supplementary Fig. S2).
Maternal and foetal IGF-1. Maternal IGF-1 levels were lower on GD17 (HI-GD17 p = 0.0276, Supplementary 
Fig. S3). In contrast, on GD18 (24 h after infusion-stop in group HI-EoOrg), IGF-1 levels did not differ between 
groups though there was a trend for decreased levels in HI-EoGest (Supplementary Fig. S3).
On GD20, HI-EoGest IGF-1 levels were reduced (p = 0.0003, Supplementary Fig. S3), whereas after an 
infusion-free period from GD17-GD20 levels were normal (HI-EoOrg, p = 0.5417).
Foetal IGF-I levels were unaffected in HI-infused animals on GD20 (Supplementary Fig. S3).
Maternal thyroid hormones and TSH. Maternal TSH levels were unaffected by insulin-infusion (data 
not shown); likewise, for T3, although there was a trend towards increased levels in HI-GD17 on GD17 
(Supplementary Fig. S4). T4 levels were increased by HI-infusion (0.0009, Supplementary Fig. S4), a similar pic-
ture was seen 24 h later (GD18) (HI-EoGest, p = 0.0112; HI-EoOrg, p = 0.0064 versus CTRL. Suppl. Fig. 4). On 
GD20, HI-EoGest group T4 levels remained elevated (p < 0.0001), whereas HI-EoOrg group levels had returned 
to control levels (Supplementary Fig. S4).
Discussion
We have previously used HI-infusion in a pregnant non-diabetic rat model to investigate the effects from continu-
ous hypoglycaemia on foetal skeletal development. We showed that maternal hypoglycaemia throughout gestation 
delays foetal growth and skeletal development, while hypoglycaemia only until after completion of organogenesis 
(GD17) allows for near-normal development6. The mechanisms underlying these developmental changes are not 
fully understood. In order to elucidate this, we extended our investigation to assess for histopathologic changes 
and potential regulatory players in foetal bone development, based on the hypothesis that hypoglycaemia disrupts 
regulation of the skeletal micro-environment. The present study clearly shows that continuous hypoglycaemia 
throughout gestation causes pronounced histopathologic changes in tibial growth plates including disproportion-
ately altered zone volumes. These changes are highly similar to changes caused by hypoxia, leading us to propose 
hypoglycaemia-induced hypoxia as a pivotal mechanism (Supplementary Fig. S5). When hypoglycaemia lasted 
only until GD17, histopathologic changes were less pronounced and growth plate volumes normal.
The observed severely disrupted ECM architecture in central foetal growth plates following hypoglycaemia 
throughout gestation may have resulted, at least in part, from decreased expression of the ECM protein MATN-3, 
essential to structural integrity of the chondrocyte scaffold7. In contrast, expression of COMP, collagen IX, and 
collagen II were unaffected, although similarly important for growth plate structural integrity through the forma-
tion of interconnected complexes with MATN-37,8. In murine growth plates, ablation of any one of these proteins 
causes a longitudinal, central disruption of the columnar chondrocyte organisation and decreased cell numbers, 
occasionally accompanied by hypertrophic chondrocytes with pyknotic nuclei9–13. These changes are very similar 
to the appearance and confinement of the histopathologic findings in the current study and those in studies by 
others following growth plate hypoxia14–17, hence the rational for our hypothesis. Reversely, MATN-3 decreases 
may be secondary to a hypoxia-induced disruption of the ECM architecture. The less pronounced chondrocyte 
disorganisation and normal MATN-3 expression after hypoglycaemia only until GD17 indicates that changes have 
either partly recovered after GD17 or the development has been attenuated. From this study, it cannot be con-
cluded which of these scenarios take place, as growth plates were not evaluated on GD17.
In support of our interpretation, extended hypoglycaemia increased expression of the hypoxia-protecting 
factors, HIF-1α and VEGF-A, at the boundaries immediately surrounding the central histopathologic changes. 
Strikingly similar histopathologic changes were recorded in growth plates following ablation of either HIF-1α or 
VEGF-A in mice14–17 and vice versa, exposure of cultured chondrocytes to hypoxia increases expression of these 
factors18–20. Moreover, in mice, growth plate hypoxia induced by chondrocyte-specific inactivation of the HIF-1α 
gene increases VEGF-A expression at the periphery of the accompanying central growth plate changes17, similar 
to our findings. In line with this, histological growth plate changes were confined to the longitudinal central area, 
which is particularly vulnerable to hypoxia, being avascular and relying on passive oxygen diffusion from adja-
cent blood vessels17,21. This suggests that the histologic growth plate changes seen here are due to central hypoxia, 
which in turn elicits a local counter-regulatory increase of HIF-1α and VEGF-A levels.
On GD20, the increased maternal corticosterone levels following hypoglycaemia throughout gestation are 
likely caused by the hypoglycaemia, and is a known counter-regulatory response, increasing glucose-output from 
the liver22, also explaining changes in maternal IGF-1 and thyroid levels23–25. Since maternal and litter plasma 
corticosterone levels correlated in the hypoglycaemic animals, we speculate that increased maternal corticos-
terone level in turn exposed the foetus to increased levels through trans-placental transport26. Subsequently, 
foetal corticosterone may have impeded vascularisation in the growth plate adjacent to the metaphyseal area. 
Corticosteroid exposure has been shown to decrease production of VEGF-A by growth plate chondrocytes in 
vitro and in vivo27,28, and induce growth plate hypoxia by decreasing density of adjacent blood vessels in mice and 
piglets27,29. This is also in line with our observation of increased HIF-1α and VEGF-A mRNA levels in foetal tibial 
and meta-tarsal joint articular cartilage, which is equally avascular and vulnerable to decreased peri-articular 
angiogenesis following increased blood corticosteroid levels in mice27,30,31. The observed secondary increases 
in anti-hypoxia factors may be a compensatory response to corticosterone-induced hypoxia. In line with this, 
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ending hypoglycaemia on GD17 and normalising corticosterone levels may have interrupted the progression of 
the histopathologic changes.
In the above studies, no central histopathologic changes were observed in growth plates following corticoster-
oid exposure, however, this does not invalidate the present working hypothesis. Unlike the present study, admin-
istration was postnatal, and it is probable that the developing skeleton may be more vulnerable to corticosteroid 
exposure; counter-regulatory measures may also differ. Furthermore, temporary dosing was used, whereas in the 
present study, foetuses were exposed to high corticosterone levels, presumably, from conception.
Hypoglycaemia throughout gestation decreased total growth plate volume as anticipated based on previously 
observed shortened tibia length in litter-mates (foetuses from the same litters used for other investigations)6, 
which are known effects of glucocorticoid-dosing in rats and rabbits32–34. The disproportionate zone volume 
changes may be linked to reduced local VEGF-A levels. VEGF-A inactivation in growing mice expands the hyper-
trophic zone in tibial growth plates35, and chondrocyte-specific VEGF-A knock-out increases hypertrophic and 
decreases degenerative zone lengths in mouse embryo tibial growth plates (through delayed maturation/removal 
of hypertrophic chondrocytes)15. This is in line with the hypothesis of a key role of hypoxia in the present changes. 
Decreased MATN-3 expression may also be implicated, since MATN-3 KO promotes chondrocyte hypertrophy 
in mouse embryos10,36; this is reflected by an increased hypertrophic zone length in tibial growth plates following 
premature maturation of proliferative into hypertrophic chondrocytes10. In contrast to hypoglycaemia lasting 
throughout gestation, hypoglycaemia ending on GD17 resulted in only slightly decreased total and separate growth 
plate volumes, which were not statistically different from controls; this was surprising given the shorter tibial 
length in litter-mates6. However, since this decrease in tibial length was less pronounced than after hypoglycaemia 
throughout gestation6, it possibly reflects delayed bone growth prior to GD17 extending beyond GD17, allowing 
only for an attenuation of the decrease.
In addition to a potential primary role of hypoxia in the development of the histopathologic growth plate 
changes, hypoglycaemia may also play an important role. The growth plate is a highly metabolic tissue, rely-
ing on anaerobic glycolysis37, and glucose serves as an essential source of energy38. Consequently, central chon-
drocytes may die due to glucose insufficiency and impaired glycolysis decreasing the energy supply. Apoptosis 
was seen despite local up-regulation of HIF-1α, which is known to increase expression of glucose transporters 
and enzymes of the glycolytic pathway39–41. However, this does not exclude a concurrent role of hypoxia in the 
changes; changes may be caused by a combination of hypoglycaemia and hypoxia.
Our data suggests that during foetal development, the growth plates are particularly vulnerable to mater-
nal hypoglycaemia, more so than the ossification process, regardless of duration. High corticosteroid levels are 
known to decrease osteoblast and increase osteoclast activity and number/life-span in bone, leading to decreased 
bone formation and increased bone resorption ultimately reducing bone mineral density30,42–44. However, follow-
ing hypoglycaemia throughout gestation, parameters relating to the bone mineralisation process did overall not 
change, in line with our previous findings of unaffected tibial peak mineral density in litter-mates in this group6.
Our investigation has some limitations; firstly, animal models are not necessarily translatable to humans, 
which should be kept in mind when interpreting the results. Moreover, pregnant diabetic women would not be 
continuously hypoglycaemic following insulin-dosing. Secondly, the rats are not diabetic, therefore the influence 
of counter-regulatory responses might differ in diabetics. This model was not intended as an animal model of 
diabetes, but rather, a model of experimentally insulin-induced hypoglycaemia, to be used as a means of under-
standing mechanisms involved in normal skeletal development.
This strengthens the study in several aspects including that it provides a stable controlled model in which all 
animals were similar at the outset and unaffected by disease. It also allows for investigation of changes to foetal 
skeletal development during hypoglycaemic conditions. Moreover, to better understand duration of continuous 
hypoglycaemia on foetal skeletal development we included both a group with insulin-induced hypoglycaemia 
throughout gestation as well as a group with hypoglycaemia only until completion of organogenesis (GD17) in order 
to also study prevention of foetal changes. Additionally, insulin-infusion was well tolerated and less stressful than 
the otherwise necessary multiple daily dosing needed to approach continuous hypoglycaemia, allowing for better 
animal welfare. Finally, the breadth of analytical methods employed provides linkage between observed histo-
pathological changes and potential regulatory factors.
In summary, this experimental rat model of insulin-induced hypoglycaemia on foetal skeletal develop-
ment shows pronounced effects on growth plate organisation; however, discontinuation of insulin-infusion 
after organogenesis allows for a partly normal development. We speculate that the skeletal changes are 
induced by hypoxia secondary to increased corticosterone levels (Supplementary Fig. S5). The hypoglycaemia 
induces a counter-regulatory increase in maternal plasma corticosterone levels, which in turn increases foe-
tal corticosterone levels, decreasing oxygen supply to central growth plates, causing hypoxia, reflected by local 
counter-regulatory increases in anti-hypoxic factors and hypoxia-like histopathologic changes. Future follow-up 
investigations to validate this hypothesis could include measurement of tissue oxygen level in the growth plates, 
as well as histologic evaluation of: i) metaphyseal vascularisation (e.g. by immunostaining for endothelial cell 
markers), ii) local HIF-1α and VEGF-A protein levels (e.g. by immunohistochemistry), to determine if they mir-
ror the mRNA changes, and iii) the apoptotic phenotype of the growth plate chondrocytes (e.g. by TUNEL assay).
In conclusion, our study underlines the importance of sufficient foetal glucose availability during late gestation 
for support of normal skeletal development.
Materials and methods
Experimental design. The study design is presented in Fig. 7 and described in detail elsewhere6, but briefly, 
female Sprague-Dawley rats (approximately ten weeks old) were continuously infused with either HI or vehicle, 
starting one week prior to mating (Day 1).
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The two experimental groups were: HI-infusion throughout and until end of gestation i.e. until gestation 
day (GD)20 (HI-EoGest); HI-infusion only until GD17 (i.e. approximate end of organogenesis) followed by a 
three-day infusion free period (HI-EoOrg). Control animals were infused with vehicle until GD20. Animals 
which died or were terminated prematurely were excluded; a total of 44 animals were infused with HI (16 
received HI-infusion until GD20 and 20 until GD17); 29 were infused with vehicle. On GD17 eight animals from 
the HI-infused and control group were sacrificed for maternal blood sampling, these sub-groups were termed 
HI-GD17 and CTRL-GD17, respectively. At the end of the study (GD20) all remaining animals were sacrificed, 
and various parameters assessed (described below).
It has been confirmed that insulin-infusion decreased maternal blood glucose levels as intended, from 3 h after 
infusion-start6; at the end of study/sacrifice HI-EoGest foetal blood glucose levels were also decreased.
All procedures involving live rats have been ethically approved by the Animals (Scientific Procedures) Act 
1986 (ASPA) and United Kingdom Secretary of State and performed according to the ARRIVE guidelines, 
Directive 2010/63/EU, EC Commission Directive 2004/10, OECD Principles and Good Laboratory Practice, and 
The Good Laboratory Practice (Codification Amendments Etc.) Regulations 200445–48, as well as Envigo and 
Novo Nordisk A/S company policies on the care and use of laboratory animals.
Sampling of foetal tissue. Within one hour of sacrifice, one foetus per litter was taken from a mid-horn 
position (alternating between left/right uterine horn) from approximately half the dams in each group (Fig. 7). 
From each foetus, the left hind limb was fixed in 10% neutral buffered formalin and paraffin embedded for his-
tology. The paraffin block was sectioned into 5 μm thick lateral longitudinal sections, mounted on glass slides, 
and stored at −20 °C until staining. The starting point was set at the first section where tissue appeared. From and 
including the first section, every fifth section was stained with haematoxylin and eosin (H&E) for histopathologic 
evaluation and quantification of growth plate zone volumes. The next slide in line after each of these sections was 
used for quantification of osteoblast-osteoclast ratios in the primary ossification centre. Sections were scanned 
(Aperio AT2 scanner, Leica Biosystems, Nussloch, Germany) and histopathologic evaluations and volume quan-
tifications were performed blinded. From a subset of animals in the CTRL and HI-EoGest group (see below), the 
next three adjacent slides (i.e. third, fourth, fifth) were used for either immunohistochemistry or in situ hybridi-
zation (see below).
Descriptive histology. Histopathologic evaluation. Foetal skeletal histopathologic changes were evaluated 
using a four-step grading scale based on severity and extent of changes (x10 and x100 magnification). Features 
for each grade were: Grade 0, no changes; Grade 1, minimal changes and only a slightly increased amount of 
Figure 7. Study design including time-frames, investigations and animal numbers. Experimental groups 
received infusion with human insulin (HI) until end of gestation (EoGest) i.e. gestation day (GD) 20 (HI-EoGest 
group) or end of organogenesis (EoOrg) on GD17 (HI-EoOrg group). NA, not analysed.
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extracellular matrix (ECM) across all zones, except the reserve zone; Grade 2, moderate changes, increased ECM 
and mild hypertrophy of chondrocytes across all zones, except the reserve zone; Grade 3, severe changes, charac-
terised by increased though remarkably hypocellular ECM. The affected area extending through all growth plate 
zones.
Immunohistochemistry. To assess structural integrity and demarcation of the hypertrophic zone in tibial 
growth plates, distribution of collagen II and X was qualitatively evaluated by light microscopy from a sub-
set of animals displaying severe (HI-EoGest group, n = 6–7 animals) or no changes (CTRL group, n = 4–5 
animals). Representative sections, 2–4 sections per animal (slide 3, 4 or 5) were selected for evaluation. 
Immunohistochemistry was not performed in HI-EoOrg animals.
To identify osteoblasts and osteoclasts in primary ossification centres, tibial sections were stained for osterix 
(in osteoblast nuclei) and CD68 (localised in lysosome membranes of osteoclasts). Protocols are included in 
Supplementary Material.
In situ hybridization. To evaluate hypoxia-related changes in foetal growth plates, distribution of anti-hypoxic 
factors HIF-1α and VEGF-A was assessed in 2–4 representative sections from animals with severe or no changes 
(i.e. HI-EoGest and CTRL groups; 5 animals/group). In situ hybridization was not performed in HI-EoOrg 
animals. mRNA signal was detected using Automated Assay for Ventana Systems. The assay RNAscope 2.5 
VS Reagent Kit-RED (322250,) Probe-Rn-Hif1a (432289) and Probe-Rn-Vegfa (315369) from Advanced Cell 
Diagnostics, Inc., Newark, CA, USA.
Quantitative histology. Stereologic quantification of volumes. The sampling method described above 
resulted in 11–22 H&E stained sections per foetus that contained growth-plate. Volumes of each growth plate 
zone and adjacent primary spongious zone were quantified based on the Cavalieri principle49. Demarcation of 
individual zones was defined according to the morphologic criteria of chondrocytes in each zone described by 
Burdan et al.50. NewCAST software (Visiopharm, Hoersholm, Denmark) was used; point-counting was based 
on preliminary counting on randomized sections, with a minimum 150–200 hit-points in total and a coeffi-
cient of error (CE) < 10%. Grid systems used 7 × 8 (reserve zone) and 12 × 12 points (remaining four zones) per 
view field (on-screen magnification x100). The sampling fraction was 100% of growth plate area on each section 
(shape factor 4, smooth organ). For each zone, volume and mean CE were calculated according to stereologic 
principles49,51.
The primary ossification centre was included in 6–18 sections/foetus. Osteoblast nuclei and osteoclast cyto-
plasm total volumes were estimated using a grid system with 2 × 2 and 5 × 5 points per view field (on-screen 
magnification x400). Sampling fraction was 100% of the primary ossification centre per section (shape factor 6, 
smooth organ). Volumes and mean CE were calculated as above followed by calculation of volume ratio.
Gene expression analysis. RT-qPCR quantification of foetal bone tissue mRNA levels. One foetus per litter 
was taken from a mid-horn position from the uterine horn (opposite to the above), hind limbs were sectioned 
at the hip-joint, soft tissue removed by microdissection, bones placed in aluminium foil envelopes, snap frozen 
in liquid nitrogen, and stored at −20 °C until RNA isolation. Total RNA was extracted using Trizol (15596026, 
Thermo Fisher Scientific, Waltham, MA, USA), purified using RNeasy Mini Kit (74104, QIAGEN AB, Sollentuna, 
Sweden), and reverse transcribed to cDNA using High-Capacity cDNA reverse Transcription Kit (4374966, 
Thermo Fisher Scientific). mRNA levels were quantified by Real-Time PCR using QuantStudio 7 Flex Real-Time 
PCR system and Taqman Gene Expression Assays (Applied Biosystems, Foster City, CA, USA).
Genes investigated included: Col10a1, Col9a1, Col2a1, Comp, Matn-3 (for structural composition of cartilage/
growth plate); Hif-1α, Vegf-A (for regulation of oxygen balance); Trap, Alp, Runx2, Rankl (for osteoblast/osteo-
clast differentiation and activity); Igf-1, Igf-R, Igfbp-3, Igfbp-5 (IGF-1 pathway). Housekeeping genes: Gapdh and 
β-actin.
Triplicate measurements were performed. If the standard deviation (SD) of mean CT values exceeded 0.167 
and one measurement was a clear outlier, this was removed. If there was no clear outlier, CT values from all three 
measurements were included in the mean. The “∆∆CT Method” was used to calculate relative expression of each 
target gene. First the target gene CT value (CT, target) was normalized to the mean CT value of the two housekeep-
ing (reference) genes, (CT, ref), for each animal and target gene separately (∆CT = CT, target-CT, ref). Thereafter, 
mean ∆CT and SD were calculated for each target gene within each group. The ∆∆CT value was then calculated 
by normalizing the group mean ∆CT for each test group to the mean ∆CT of the control group (∆∆CT = mean 
∆CT, test group - mean ∆CT, control group). Data are reported as −∆∆CT values.
Quantification of hormones in plasma. Sampling of blood for quantification of plasma hormone levels 
was performed on the following days:
Maternal: on GD17, groups CTRL-GD17 (n = 8) and HI-GD17 (n = 8) were sacrificed and sampled. On 
GD18, CTRL, HI-EoGest, and HI-EoOrg groups were sampled (approximately 24 h after infusion-stop in the 
HI-EoOrg animals). On GD20, at sacrifice, all dams and litters (pooled blood) were sampled.
Plasma corticosterone. Plasma corticosterone (maternal and foetal) was quantified using a commercial ELISA 
kit (EIA-5186, DRG International, Springfield, New Jersey, USA). Plasma was stored at −20 °C before analysis. 
Lower limit of quantification (LLOQ): 50 nM.
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Plasma insulin-like growth factor 1 (IGF-1). Plasma was pre-treated with a proprietary “releasing agent” to dis-
place all IGF-1 bound to binding protein. IGF-1 (maternal and foetal) was quantified using a commercially avail-
able ELISA kit (E25, Mediagnost, Reutligen, Germany). LLOQ: 0.029 ng/ml.
Plasma thyroid hormones and thyroid stimulating hormone (TSH). Plasma thyroid hormone (T4 and T3 - 
maternal) and TSH (maternal and foetal) was quantified using commercially available assays (STTHMAG-21K; 
Milliplex MAP Rat TSH Pituitary Panel (RPTMAG-86K, both Millipore (U.K) Ltd, Hertfordshire, UK). LLOQ: 
T4 (1.95 ng/ml), T3 (0.391 ng/ml) and TSH (123 pg/ml). Measurements were performed in duplicate. Reported 
means are from individual dams/litters.
Statistics. Histopathology. Incidence and severity of histopathologic changes were compared between 
groups using Fishers exact test.
Stereology. In each animal total growth plate volume was calculated as the sum of each zone (reserve, prolifer-
ative, hypertrophic, degenerative). Also calculated for each zone were: the volume of each zone relative to total 
growth plate volume; the ratios of spongious zone: growth plate and osteoblast: osteoclast volume. Group means 
were compared using one-way ANOVA.
qPCR. For each target gene, ∆∆CT values were compared using one-way ANOVA.
Plasma hormone levels. Comparisons between groups were analysed using one-way ANOVA unless more than 
one sample/group was <LLOQ, in which case Kruskal-Wallis with a post hoc Dunn’s multiple comparisons test 
was used. Results from GD17 were compared using an unpaired two-tailed t-test.
Overall, when one-way ANOVA was used and when there was a significant effect of group, a post hoc Tukey’s 
multiple comparisons test was performed. A p-value <0.05 was considered statistically significant.
Data availability
Data are available upon request.
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